申请人:Agency for Science, Technology and Research
公开号:US20220288102A1
公开(公告)日:2022-09-15
Described herein is a compound selected from the group consisting of AZ960, CYC116, MI-3, Nexturastat A, TAK-901, Tubastatin A hydrochloride salt, and a small interfering RNA molecule comprising any one of SEQ ID No. 5 to SEQ ID No. 28 for use in the treatment of Hepatitis B. The compound may also be used in the manufacture of a medicament for the treatment of Hepatitis B. Also described is a method of treating a Hepatitis B infection in a subject, the method comprises administering to the subject a therapeutically effective dose of the compound as described above.